Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Cipla receives FDA approval for generic nintedanib capsules targeting idiopathic pulmonary fibrosis treatment
Small molecule, respiratory disease, tyrosine kinase inhibitor, idiopathic pulmonary fibrosis, generic drug - Read more

MediWound, Vericel awarded BARDA contract for NexoBrid worth up to $197 million
Government contract, manufacturing agreement, enzymatic therapeutics, milestone payments - Read more

Biodexa Pharmaceuticals, Syngene partner to manufacture MTX240 GMP clinical trial supplies for gastrointestinal cancers
Manufacturing agreement, oncology, small molecule, rare disease - Read more

Transgene licenses NEC Bio's AI neoantigen prediction platform for TG4050, €5M ($5.77M) plus milestones
Licensing deal, oncology, AI/ML, personalized medicine, milestone payments - Read more

TriNetX, Regeneron Pharmaceuticals collaborate on exclusive access to 300 million patient health records for drug discovery
Data licensing collaboration, drug discovery, digital health, AI/ML, genomics - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

AstraZeneca's Imfinzi (durvalumab) quadruplet regimen hits Ph3 primary endpoint in unresectable hepatocellular carcinoma
Antibody, cancer, PD-L1 inhibitor, hepatocellular carcinoma, combination therapy, CTLA-4 - Read more

Novo Nordisk claims indirect data show oral Wegovy outperforms Eli Lilly's Foundayo in obesity treatment comparison
Small molecule, obesity, competitive, strategic - Read more

Epia Neuro launches with BCI device helping stroke patients translate brain signals into functional movement
Brain-computer interface, neurological, strategic, operational - Read more

Eli Lilly's obesity pill Foundayo gains analyst forecasts of 5M+ prescriptions, $1.6B revenue potential in 2026
GLP-1 receptor agonist, obesity, strategic, revenue impact, competitive - Read more

Esperion Therapeutics raises $50M royalty financing, supports strategic acquisition of Corstasis Therapeutics
Cardiovascular, small molecule, commercial-stage, bempedoic acid - Read more

Hoth Therapeutics raises $2M registered direct offering, clinical-stage biopharmaceutical company
Clinical-stage, biopharmaceutical, unmet medical needs, patient-centric - Read more

Generare raises €20M ($23M) Series A, building molecular data library for drug discovery
Platform technology, drug discovery, natural products, AI-driven - Read more

Adragos Pharma buys Sanofi sterile injectables plant for undisclosed price
Acquisition, manufacturing agreement, sterile injectables, CDMO services - Read more

Anthropic acquires stealth biotech Coefficient Bio for $400M to expand AI-driven drug research and development capabilities
AI platform, drug development, strategic, major transaction - Read more

UK signs pharmaceutical partnership with US, securing tariff-free drug exports while boosting NHS medicine prices 25%
Strategic, financial, investment, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Glenmark drops Hikma partnership to directly commercialize Ryaltris allergy spray in US market
Commercialization, allergy, direct marketing, partnership termination - Read more

Takeda, Denali Therapeutics end dementia partnership, returning DNL593 FTD-GRN treatment to Denali
Partnership termination, neurological, protein therapy, co-development - Read more

Alto Neurosciences halts ALTO-101 PDE4 inhibitor development after Ph2 failure in cognitive impairment associated with schizophrenia
Small molecule, neurological, PDE4 inhibitor, schizophrenia, cognitive impairment, transdermal delivery - Read more

Immunovant's batoclimab fails Ph3 thyroid eye disease trials targeting FcRn receptor pathway
Antibody, autoimmune, FcRn inhibitor, thyroid eye disease, monoclonal antibody - Read more

Lipocine's LPCN 1154 (oral brexanolone) fails Ph3 primary endpoint for postpartum depression treatment
Small molecule, neurological, postpartum depression, brexanolone, oral delivery - Read more

Biopharma R&D pipeline shrinks 3.9% to 22,940 drugs, marking first decline in 30 years
Pipeline development, oncology, strategic, operational - Read more

Trump imposes 100% pharma tariffs with carve-outs; major companies like Pfizer, J&J face potential levies
Pharmaceuticals, regulatory, strategic, financial - Read more

Ferring Pharmaceuticals terminates two Ph1 trials of FE999302 (choriogonadotropin beta) for infertility treatment
Protein therapy, reproductive health, follicle-stimulating hormone, fertility treatment, combination therapy - Read more

BioNTech shuts Singapore mRNA manufacturing site by February amid pipeline diversification and declining vaccine demand
mRNA vaccine, infectious disease, operational, cost reduction - Read more

Gilead Sciences terminates WONDERS-2 Ph2/3 trial testing GS-1720 (integrase inhibitor) combination for human immunodeficiency virus treatment
Small molecule, infectious disease, integrase inhibitor, HIV, capsid inhibitor, combination therapy - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here